Nexviazyme® (avalglucosidase alfa-ngpt) – New orphan drug approval
August 6, 2021 - The FDA announced the approval of Sanofi’s Nexviazyme (avalglucosidase alfa-ngpt), for the treatment of patients 1 year of age and older with late-onset Pompe disease (LOPD) [lysosomal acid alpha-glucosidase (GAA) deficiency].
Top